First Line

A treatment for advanced HIV-associated Kaposi’s sarcoma is relaunched by Chael Needle Newly acquired by Galen from Gilead Sciences, DaunoXome (daunorubicin citrate liposome injection) is an...

Protecting the Pipeline

LifeGuide HIV drug development faces challenges by Jeannie Wraight and Mariel Selbovitz, MPH Triple and now quad drugs like Gilead’s Atripla and their new compound known...

Status Update

LifeGuide Based in San Diego, a prevention model aims to reach everyone Everybody should be tested for HIV. That message is the basis for Lead...

Treatment as Prevention

LifeGuide A community perspective on PrEP delves into its pros & cons by Jeannie Gibbs Post-exposure prophylaxis (PrEP) is the provision of antiretrovirals (ARVs) to HIV-negative...

Skin Cancers Revisited

Sun Blocked A new study examines non-melanoma skin cancers & HIV by Chael Needle In the pre-HAART era, an AIDS diagnosis or even an HIV-positive diagnosis illuminated...

HPV Immunotherapy Research

Warts & All An immunotherapy candidate seeks to address complications from HPV by Chael Needle Human papillomavirus (HPV) is the most common sexually transmitted infection, but, according...

Bathroom Reading

A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...

Preventative HIV Vaccine

Express Lane A Vaccine Candidate Seeks to Prevent—Not Just Control—HIV Infection by Chael Needle Preventative HIV vaccine research has taken another step. The candidate, a granulocyte-macrophage colony stimulating factor...

Safety Net

Treatment Horizons by Chael Needle A nonprofit creates a new support system for the uninsured Joining Merck and ViiV Healthcare, Gilead Sciences is now supporting and...

Verve for VERxVE

An extended release formulation breaks through by Chael Needle Based on results from the VERxVE study, the FDA recently approved Viramune XR for use in antiretroviral...